Literature DB >> 26636527

Serum uric acid and inflammation in patients with immune thrombocytopenic purpura: preliminary results.

M S Dal1, A Karakus, B B Aydin, M O Ekmen, T Ulas, O Ayyildiz.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the uric acid (UA) and C-reactive protein (CRP) levels in patients with immune thrombocytopenic purpura (ITP). PATIENTS AND METHODS: Forty patients with newly diagnosed ITP and 40 healthy individuals were enrolled in the study. The patients were divided into two groups; group 1 (n = 40) consisted of patients with ITP, and group 2 (n = 40) consisted of healthy subjects. UA and CRP levels were measured in the blood samples from them.
RESULTS: There were no statistical differences in gender, age and body mass index between two groups (p > 0.05 for all). Compared to group 2, group 1 had significantly higher UA levels (p = 0.002), whereas CRP levels were not significantly different (p > 0.05). In ITP patients, serum UA and CRP levels significantly correlated with low platelet count (r = -0.362, p = 0.022; r = -0.383, p = 0.015, respectively); and UA levels significantly correlated with CRP levels (r = 0.436, p = 0.005).
CONCLUSIONS: The present study showed that UA levels increased in patients with ITP and negatively correlated with platelet counts. UA levels might be a mediator of inflammation via enhanced production of inflammatory cytokines; they might also be a potential mediator of low platelet count, and could play a pathophysiological role in the development of ITP.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26636527

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Serum Copper and Zinc Levels in Primary Immune Thrombocytopenia.

Authors:  Gülden Sincan; Fuat Erdem; İlker Bay; Suat Sincan
Journal:  Biol Trace Elem Res       Date:  2022-05-30       Impact factor: 4.081

2.  Inflammation-Related Gene Polymorphisms Associated With Primary Immune Thrombocytopenia.

Authors:  Ju Li; Sai Ma; Linlin Shao; Chunhong Ma; Chengjiang Gao; Xiao-Hui Zhang; Ming Hou; Jun Peng
Journal:  Front Immunol       Date:  2017-06-28       Impact factor: 7.561

3.  Integrated Network Pharmacology and Metabolomics Analysis of the Therapeutic Effects of Zi Dian Fang on Immune Thrombocytopenic Purpura.

Authors:  Yubo Li; Yamei Li; Wenliang Lu; Hongbin Li; Yuming Wang; Houmin Luo; Yuanyuan Wu; Wenying Dong; Gang Bai; Yanjun Zhang
Journal:  Front Pharmacol       Date:  2018-06-19       Impact factor: 5.810

4.  Teetering on a liver's edge: a case report highlighting clinical decision-making in thrombocytopenia.

Authors:  Adam Yan; Laura Erdman; Lillian Sung; Stacey Bernstein
Journal:  BMC Cancer       Date:  2019-11-06       Impact factor: 4.430

5.  Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation.

Authors:  Ming Jing Wang; Yan Sun; Ying Song; Ju Ning Ma; Zi Qing Wang; Xiao Qing Ding; Hai Yan Chen; Xue Bin Zhang; Min Min Song; Xiao Mei Hu
Journal:  Front Med (Lausanne)       Date:  2022-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.